Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Stony Brook University Medical Center
mi
from
Stony Brook, NY
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Gynecologic Oncology Network
mi
from
Greenville, NC
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Gynecologic Oncology Network
mi
from
Greenville, NC
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Mount Carmel Health Center West
mi
from
Columbus, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Mount Carmel Health Center West
mi
from
Columbus, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Miami Valley Hospital
mi
from
Dayton, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Cancer Care Associates-Midtown
mi
from
Tulsa, OK
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Cancer Care Associates-Midtown
mi
from
Tulsa, OK
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Tulsa Cancer Institute, Pllc
mi
from
Tulsa, OK
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Tulsa Cancer Institute, Pllc
mi
from
Tulsa, OK
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Abington Memorial Hospital
mi
from
Abington, PA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Women and Infants Hospital
mi
from
Providence, RI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
M D Anderson Cancer Center
mi
from
Houston, TX
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
University of Washington Medical Center
mi
from
Seattle, WA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Northwest Medical Specialties
mi
from
Tacoma, WA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Saint Vincent Hospital
mi
from
Green Bay, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Saint Mary's Hospital
mi
from
Green Bay, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
MedStar Washington Hospital Center
mi
from
Washington,
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  3/27/2018
Shawnee Mission Medical Center
mi
from
Shawnee Mission, KA
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 3/27/2018
Shawnee Mission Medical Center
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy
Prospective, Double Arm, Comparative Study for the Evaluation of Postoperative Pain, QOL, and Determination of Inflammatory Markers In Patients Undergoing Robotics Versus Open Laparotomy Approach for Staging of Endometrial Cancer
Status: Enrolling
Updated:  3/30/2018
Ohio State University
mi
from
Columbus, OH
Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy
Prospective, Double Arm, Comparative Study for the Evaluation of Postoperative Pain, QOL, and Determination of Inflammatory Markers In Patients Undergoing Robotics Versus Open Laparotomy Approach for Staging of Endometrial Cancer
Status: Enrolling
Updated: 3/30/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer
Status: Enrolling
Updated:  4/4/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer
Status: Enrolling
Updated: 4/4/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Retina-Vitreous Assoc Med Grp
mi
from
Beverly Hills, CA
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Retina-Vitreous Assoc Med Grp
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Dr. Andrew Gardner Logan, FL
mi
from
Tamarac, FL
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Dr. Andrew Gardner Logan, FL
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Perez & Perez, MDs PA
mi
from
Tampa, FL
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Perez & Perez, MDs PA
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Emory University Hospital
mi
from
Atlanta, GA
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Northwestern University
mi
from
Chicago, IL
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Rush University Medical Center
mi
from
Chicago, IL
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Ellsworth Uveitis & Retina Car
mi
from
Ellsworth, ME
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Ellsworth Uveitis & Retina Car
mi
from
Ellsworth, ME
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Kresge Eye Institute
mi
from
Detroit, MI
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Kresge Eye Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Metro Eye Res and Surgery Inst
mi
from
Palisades Park, NJ
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Metro Eye Res and Surgery Inst
mi
from
Palisades Park, NJ
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
New York Eye & Ear Infirmary
mi
from
New York, NY
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
New York Eye & Ear Infirmary
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Wake Forest Univ HS
mi
from
Winston-Salem, NC
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Wake Forest Univ HS
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Dean McGee Eye Institute
mi
from
Oklahoma City, OK
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Dean McGee Eye Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Oregon Health and Science University
mi
from
Portland, OR
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated:  4/4/2018
Texas Retina Associates
mi
from
Dallas, TX
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Status: Enrolling
Updated: 4/4/2018
Texas Retina Associates
mi
from
Dallas, TX
Click here to add this to my saved trials